Evicenter
P&T meetings

BIM-IOL System

Open-angle glaucoma or ocular hypertension

Manufacturer
SpyGlass Pharma
Regulatory submission
NDA planned for 2028
Launch
Not announced
Last updated
129 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of other drugs on BIM-IOL System

2 evidence topics · 2 sources

Additional prostaglandin analog dosing: Lumigan labeling

“LUMIGAN® (bimatoprost ophthalmic solution) 0.01% should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may decrease the intraocular pressure lowering effect.” (opens the source at this quote in a new tab)

Protocol medication exclusions: first-in-human study

“Any medication in the fellow eye that would impact IOP in the study eye” (opens the source at this quote in a new tab)

“Use of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) or similar medications” (opens the source at this quote in a new tab)

Clinical drug interaction studies

No evidence found.